Sionna Therapeutics, Inc. (SION)
| Market Cap | 150.63M -90.8% |
| Revenue (ttm) | n/a |
| Net Income | -109.52M |
| EPS | -2.43 |
| Shares Out | 45.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 470,236 |
| Open | 3.430 |
| Previous Close | 3.430 |
| Day's Range | 3.250 - 3.575 |
| 52-Week Range | 3.190 - 54.970 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 21.00 (+530.63%) |
| Earnings Date | Nov 10, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SION stock is "Hold." The 12-month stock price target is $21.0, which is an increase of 530.63% from the latest price.
News
Sionna Therapeutics reports Q3 EPS (72c), consensus (68c)
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination,” said Mike Cloonan, President and Chief E...
Sionna Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
PreciSION missed its target; post hoc work suggested non-adherence, lower TRIKAFTA exposure and possible potentiator-related anti-synergy, alongside NBD1 activity. A 28-day dual-corrector phase II proof-of-concept study is planned for Q1 2027, with cash runway into H2 2029.
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027
Sionna Therapeutics Earnings release: Q3 2026
Sionna Therapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Sionna Therapeutics Quarterly report: Q3 2026
Sionna Therapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Sionna Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
The August PreciSION CF result was disappointing, with lower Trikafta exposure in the four-drug regimen; the next focus is a two-drug NBD1/TMD1 combination. A U.S. phase II study is planned for Q1 2027, with cash runway into H2 2029.
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF),...
Sionna Therapeutics to present at 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics (SION) “announced data being presented at the 2026 North American Cystic Fibrosis Conference (NACFC) being held in Atlanta, Georgia on October 7-10, 2026. The oral presentation by ...
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 s...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Sionna Therapeutics price target raised to $6 from $5 at Wedbush
Wedbush raised the firm’s price target on Sionna Therapeutics (SION) to $6 from $5 and keeps a Neutral rating on the shares. The firm notes the company released additional post…
Sionna Therapeutics Transcript: Study update
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to a dual combination strategy with SION-451 plus SION-2222. The AscenSION CF phase IIa trial will begin in Q1 2027 to evaluate this approach.
Sionna Therapeutics Press release: Study update
Sionna Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Sionna Therapeutics Slides: Study update
Sionna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial
Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Phase 2a proof-of-concept, or POC, trial, and results from...
Sionna Therapeutics to reduce workforce by 46%
Following the completion of a comprehensive review of its operations, Sionna’s board of directors has approved a workforce reduction of approximately 46% and the company has implemented other cost-sav...
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and direc...
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
SAN DIEGO--(BUSINESS WIRE)---- $SION #Health--Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and ...
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics
Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potentia...
Sionna Therapeutics rises 15.9%
Sionna Therapeutics (SION) is up 15.9%, or 71c to $5.21.
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeu...
Sionna Therapeutics price target lowered to $5 from $38 at Freedom Broker
Freedom Broker analyst Ilya Zubkov lowered the firm’s price target on Sionna Therapeutics (SION) to $5 from $38 and keeps a Hold rating on the shares, telling investors that the…
Sionna Therapeutics rises 14.0%
Sionna Therapeutics (SION) is up 14.0%, or 63c to $5.13.